环青霉素的药理学及体外评价：作为治疗淋病奈瑟菌感染潜在单剂量疗法的评估
Pharmacological and in vitro evaluation of cyclacillin: assessment as potential single-dose therapy for treatment of Neisseria gonorrhoeae infection.
作者信息
Wagner K F, Blair A D, Counts G W, Holmes K K
出版信息
Antimicrob Agents Chemother. 1980 Jan;17(1):89-91. doi: 10.1128/AAC.17.1.89.
The pharmacokinetic properties of cyclacillin administered as a 3.0-g oral dose, with and without progenecid, have been studied and correlated with in vitro activity of the drug against 109 isolates of Neisseria gonorrhoeae. By 8 h after dosage, levels of cyclacillin in serum declined below the minimal inhibitory concentration and the inferior antibacterial activity of cyclacillin (compared with that of amipicillin) suggest that cyclacillin is not a promising alternative to ampicillin for single-dose treatment of gonorrhea.
已对口服3.0克环青霉素（无论有无丙磺舒）后的药代动力学特性进行了研究，并将其与该药物对109株淋病奈瑟菌的体外活性相关联。给药后8小时，血清中环青霉素水平降至最低抑菌浓度以下，且环青霉素（与氨苄西林相比）较差的抗菌活性表明，环青霉素并非单剂量治疗淋病时氨苄西林的理想替代药物。
Zotero 插件